Prexasertib Shrinks Ovarian Cancer Tumors in a Third of Phase 2 Trial Participants

Prexasertib Shrinks Ovarian Cancer Tumors in a Third of Phase 2 Trial Participants
The DNA repair inhibitor prexasertib shrank the tumors of a third of the ovarian cancer patients treated with it in a Phase 2 clinical trial, preliminary results show. Its developer, Eli Lilly, said the participants had recurring cancer that failed to respond to platinum-based chemotherapy. The specific form was high-grade serious ovarian carcinoma —or HGSOC — without BRCA gene mutations.

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *